يعرض 1 - 20 نتائج من 197 نتيجة بحث عن '"Medicaments antivírics"', وقت الاستعلام: 0.50s تنقيح النتائج
  1. 1
    Dissertation/ Thesis

    المؤلفون: Santos Bravo, Marta

    المساهمون: University/Department: Universitat de Barcelona. Facultat de Medicina i Ciències de la Salut

    Thesis Advisors: Marcos, Ma. Angeles, Sánchez-Palomino, Sonsoles

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  2. 2
    Dissertation/ Thesis

    المؤلفون: Martín López, Juan

    المساهمون: University/Department: Universitat de Barcelona. Facultat de Farmàcia i Ciències de l'Alimentació

    Thesis Advisors: Vázquez Cruz, Santiago

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  3. 3
    Dissertation/ Thesis

    المؤلفون: Arista Romero, Maria

    المساهمون: University/Department: Universitat de Barcelona. Facultat de Física

    Thesis Advisors: Albertazzi, Lorenzo, Pujals Riatós, Sílvia, Samitier i Martí, Josep

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  4. 4
    Dissertation/ Thesis

    المؤلفون: Petit Roig, Elena

    المساهمون: University/Department: Universitat de Barcelona. Departament de Química Inorgànica i Orgànica

    Thesis Advisors: Vilarrasa i Llorens, Jaume, Costa i Arnau, Anna M.

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  5. 5
    Dissertation/ Thesis

    المساهمون: University/Department: Universitat de Barcelona. Departament de Genètica, Microbiologia i Estadística

    Thesis Advisors: Pintó Solé, Rosa María, Bosch, Albert

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  6. 6
    Dissertation/ Thesis

    المؤلفون: Lens Garcia, Sabela

    المساهمون: University/Department: Universitat de Barcelona. Facultat de Medicina

    Thesis Advisors: Forns Bernhardt, Xavier

    المصدر: TDX (Tesis Doctorals en Xarxa)

    Time: 616.4

    وصف الملف: application/pdf

  7. 7
    Dissertation/ Thesis

    المؤلفون: Kaczmarska, Zuzanna

    المساهمون: University/Department: Universitat de Barcelona. Departament de Bioquímica i Biologia Molecular (Farmàcia)

    Thesis Advisors: Coll Capella, Miquel

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  8. 8
    Dissertation/ Thesis

    المؤلفون: Velasco Turbau, Javier

    المساهمون: University/Department: Universitat de Barcelona. Departament de Química Orgànica

    Thesis Advisors: Ariza Piquer, Xavier, Farràs i Soler, Jaume

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  9. 9
    Dissertation/ Thesis

    المؤلفون: González-Ortega, Emmanuel

    المساهمون: University/Department: Universitat de Barcelona. Departament de Bioquímica i Biologia Molecular (Farmàcia)

    Thesis Advisors: Esté Araque, José A., Marrero González, Pedro F.

    المصدر: TDX (Tesis Doctorals en Xarxa)

    وصف الملف: application/pdf

  10. 10
    Academic Journal

    المساهمون: Institut Català de la Salut, Ji F Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Tran S Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA. Ogawa E Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan. Huang CF Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung. Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung. Suzuki T Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Wong YJ Gastroenterology & Hepatology, Changi General Hospital, Singhealth, Singapore. Singhealth Duke-NUS Medicine Academic Clinical Program, Singapore. Vargas-Accarino E Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Buti M Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat de Malalties Hepàtiques, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Journal of Clinical and Translational Hepatology;12(7); https://doi.org/10.14218/JCTH.2024.00089; Ji F, Tran S, Ogawa E, Huang CF, Suzuki T, Wong YJ, et al. Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study. J Clin Transl Hepatol. 2024 Jul 28;12(7):646–58.; https://hdl.handle.net/11351/11773

  11. 11
    Academic Journal

    المساهمون: Institut Català de la Salut, Sonneveld MJ, Brakenhoff SM Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Chiu SM Department of Internal Medicine, Koahsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Park JY Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Kaewdech A Faculty of Medicine, Prince of Songkla University, Hatyai, Thailand. Seto WK Department of Medicine, State Key Laboratory for Liver Research, School of Clinical Medicine, The University of Hong Kong, Hong Kong. Buti M Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ciberehd del Intituto Carlos III de Barcelona, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Gastroenterology;166(1); https://doi.org/10.1053/j.gastro.2023.09.033; Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, et al. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy. Gastroenterology. 2024 Jan;166(1):168-177.e8.; https://hdl.handle.net/11351/10913

  12. 12
    Academic Journal

    المساهمون: Institut Català de la Salut, Marzo B Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Hepatologia, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vidal Jordana A, Castilló J, Tintore M, Montalban X Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Robles Sanchez MA Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Recerca Multidisciplinari d’Infermeria, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Otero Romero S Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Buti M, Riveiro Barciela M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Hepatologia, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Journal of Neurology;271; https://doi.org/10.1007/s00415-023-11973-y; Marzo B, Vidal-Jordana A, Castilló J, Robles-Sanchez MA, Otero-Romero S, Tintore M, et al. Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study. J Neurol. 2024;271:134–40.; https://hdl.handle.net/11351/10931; 001066392100003

  13. 13
    Academic Journal

    المساهمون: Institut Català de la Salut, Fung SK Department of Medicine, University of Toronto, Ontario, Toronto, Canada. Pan CQ Division of Gastroenterology and Hepatology, NYU Langone Health, New York University Grossman School of Medicine, New York, New York, USA. Lai-Hung Wong G Medical Data Analytics Centre (MDAC), Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China. Seto WK Department of Medicine and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong Special Administrative Region, China. Ahn SH Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Chen CY Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chiayi City, Taiwan. Buti M Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. IBER-EHD del Institute Carlos III, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Alimentary Pharmacology & Therapeutics;59(2); https://doi.org/10.1111/apt.17764; Fung SK, Pan CQ, Wong GLH, Seto WK, Ahn SH, Chen CY, et al. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks. Aliment Pharmacol Ther. 2024 Jan;59(2):217–29.; https://hdl.handle.net/11351/10898; 001098122800001

  14. 14
    Academic Journal

    المساهمون: Institut Català de la Salut, Graf C, Vermehren J Department of Internal Medicine 1, University Hospital, Goethe University, Frankfurt, Germany. D’Ambrosio R, Degasperi E Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. Paolucci S Microbiology and Virology Department, Foundation IRCCS San Matteo, Pavia, Italy. Llaneras J, Buti M Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: JHEP Reports;6(3); https://doi.org/10.1016/j.jhepr.2023.100994; Graf C, D’Ambrosio R, Degasperi E, Paolucci S, Llaneras J, Vermehren J, et al. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. JHEP Reports. 2024 Mar;6(3):100994.; https://hdl.handle.net/11351/11102

  15. 15
    Academic Journal

    المساهمون: Institut Català de la Salut, Hedskog C Gilead Sciences, Inc., Foster City, CA, USA. Spinner CD TUM School of Medicine and Health, Department of Clinical Medicine—Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, Munich, Germany. Protzer U German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany. Institute of Virology, Technical University of Munich School of Medicine, Munich, Germany. Institute of Virology, Helmholtz Munich, Munich, Germany. Hoffmann D German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany. Institute of Virology, Technical University of Munich School of Medicine, Munich, Germany. Ko C Institute of Virology, Technical University of Munich School of Medicine, Munich, Germany. Institute of Virology, Helmholtz Munich, Munich, Germany. Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon, Republic of Korea. Gottlieb RL Center for Advanced Heart and Lung Disease, Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA. Baylor Scott & White Research Institute, Dallas, TX, USA. Department of Internal Medicine, Texas A&M Health Science Center, Dallas, TX, USA. Department of Internal Medicine, Burnett School of Medicine at TCU, Fort Worth, TX, USA. Ferrer R, Antón A, Andrés C, Casares V Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Viruses;16(4); https://doi.org/10.3390/v16040546; Hedskog C, Spinner CD, Protzer U, Hoffmann D, Ko C, Gottlieb RL, et al. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials. Viruses. 2024 Mar 31;16(4):546.; https://hdl.handle.net/11351/11403

  16. 16
    Academic Journal
  17. 17
    Academic Journal
  18. 18
    Academic Journal

    المساهمون: Institut Català de la Salut, Colomer-Castell S, Campos C, Quer J Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Gregori J, Vico-Romero J Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Garcia-Cehic D Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Riveiro-Barciela M, Buti M, Esteban JI Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Rando-Segura A Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Servei de Microbiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Ibañez-Lligoña M Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Adombi CM Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Institute of Agropastoral Management, University Peleforo Gon Coulibaly, Korhogo, Côte d’Ivoire. Cortese MF, Tabernero D, Rodriguez-Frias F Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Servei de Bioquímica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: International Journal of Molecular Sciences;24(24); https://doi.org/10.3390/ijms242417185; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PID2021-126447OB-I00; info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00301; info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F00258; Colomer-Castell S, Gregori J, Garcia-Cehic D, Riveiro-Barciela M, Buti M, Rando-Segura A, et al. In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments. Int J Mol Sci. 2023 Dec 6;24(24):17185.; https://hdl.handle.net/11351/10867; 001130796900001

  19. 19
    Academic Journal

    المساهمون: Institut Català de la Salut, Sonneveld MJ, Brakenhoff SM Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. Chiu SM Department of Internal Medicine, Koahsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Park JY Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. Kaewdech A Faculty of Medicine, Prince of Songkla University, Hatyai, Thailand. Seto WK Department of Medicine, State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong. Buti M Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ciberehd del Intituto Carlos III de Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: JHEP Reports;5(8); https://doi.org/10.1016/j.jhepr.2023.100790; Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, et al. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study. JHEP Reports. 2023 Aug;5(8):100790.; https://hdl.handle.net/11351/10092

  20. 20
    Academic Journal

    المساهمون: Institut Català de la Salut, Janssen HLA Toronto General Hospital, Toronto, Ontario, Canada. Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands. Hou J Nanfang Hospital, Southern Medical University, Guangzhou, China. Asselah T Université de Paris Cité, INSERM UMR1149, Hôpital Beaujon AP-HP, Clichy, France. Chan HLY The Chinese University of Hong Kong, Hong Kong SAR, China. Zoulim F Hospices Civils de Lyon and Lyon University & INSERM U1052-Cancer Research Institute of Lyon, Lyon, France. Tanaka Y Department of Gastroenterology and Hepatology, Kumamoto University, Kumamoto, Japan. Buti M Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERHED del Instituto Carlos III, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    Relation: Gut;72(7); http://dx.doi.org/10.1136/gutjnl-2022-328041; Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, et al. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut. 2023 Jul;72(7):1385–98.; https://hdl.handle.net/11351/9744; 000921642100001